Health Care [ 6/12 ] | Life Sciences Tools & Services [ 59/73 ]
NASDAQ | Common Stock
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products.
The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025.
The company was founded in 2019 and is based in Naples, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 25 | -5.46 Increased by +95.00% | - |
| May 15, 25 | -19.86 Increased by +72.63% | - |
| Mar 28, 25 | -2.15 Increased by +90.62% | - |
| Sep 30, 24 | -111.20 Decreased by -2.32 K% | - |
| Jun 30, 24 | -109.33 Decreased by -32.50% | - |
| Mar 31, 24 | -72.55 Decreased by -248.63% | - |
| Dec 31, 23 | -22.91 Decreased by -76.47 K% | - |
| Sep 30, 23 | -4.60 Decreased by -46.14 K% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 671.99 M Increased by +11.20% | -6.03 M Decreased by -11.98% | Decreased by -0.90% Decreased by -0.71% |
| Mar 31, 25 | 624.86 M Increased by +16.65% | -5.15 M Decreased by -44.11% | Decreased by -0.82% Decreased by -23.54% |
| Dec 31, 24 | 1.08 B Increased by +N/A% | -2.41 M Decreased by -235.24% | Decreased by -0.22% Decreased by N/A% |
| Sep 30, 24 | 654.93 M Increased by +N/A% | -6.46 M Decreased by -425.33% | Decreased by -0.99% Decreased by N/A% |
| Jun 30, 24 | 604.34 M Increased by +N/A% | -5.38 M Decreased by -210.62% | Decreased by -0.89% Decreased by N/A% |
| Mar 31, 24 | 535.67 M Increased by +N/A% | -3.57 M Decreased by -113.58% | Decreased by -0.67% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | 1.78 M Increased by +157.93% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | 1.99 M Increased by +307.74% | Increased by +N/A% Decreased by N/A% |